Axsome Therapeutics (NASDAQ:AXSM) announced Wednesday a settlement agreement with U.K.-based Hikma Pharmaceuticals ...

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...

AMMAN — Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 ...

Shares in Hikma Pharmaceuticals came under pressure in early trading on Wednesday, despite a jump in annual revenues, after ...

The Group reported revenue growth of 9% (9% in constant currency) to $3.127 billion compared to $2.875 billion in 2023) ...

Hikma Pharmaceuticals PLC HIK shares dropped 6.18% to £21.54 Wednesday, on what proved to be an all-around positive trading ...

Looking ahead, revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Pharmaceuticals industry in the United Kingdom.

Hikma Pharmaceuticals reported a strong financial performance for 2024, with revenue rising nine per cent to $3.13bn (£2.47bn ...

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and ...

(Alliance News) - Hikma Pharmaceuticals PLC on Wednesday said it planned to increased spending on research and development to support further growth after reporting strong annual results. The ...

As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Similar patent litigation brought by ...

Looking ahead, revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 5.3% growth forecast ...